Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05,

01/08/12, 04/03/13	
Name of ontity	
Name of entity  EML Payments Limited	_
LML1 ayments Limited	
ABN	
93 104 757 904	
We (the entity) give ASX the follow	ving information.

\*Class of \*securities issued or to

to be issued (if known) or

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- Fully Paid Ordinary Shares be issued Number of \*securities issued or 2 43,268 Fully Paid Ordinary Shares
- maximum number which may be issued 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid

+securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Nil consideration
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of Options (The relevant options vested on 13 November 2019 and had an expiring of 13 January 2020)
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	43,268

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6g	If *securities issued under rule
	7.1A, was issue price at least
	75% of 15 day VWAP as
	calculated under rule 7.1A.3?
	Include the *issue date and both
	values. Include the source of the
	VWAP calculation

N/A

6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

Remaining capacity under 7.1 – 26,353,673 Remaining capacity under 7.1A – N/A

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

43,268 Ordinary Shares: 20 November 2019

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
299,236,466	EML fully paid ordinary shares
82,192	EML fully paid ordinary shares in escrow to 28/3/2020
	Total: 299,318,658

<sup>+</sup> See chapter 19 for defined terms.

7
(7

Number	+Class
1,452,341	Nil exercise price, options expiring 30/09/20, vesting upon achievement of performance hurdles 30/8/2020.
250,168	Nil exercise price, options vesting in two equal tranches on 28/06/2020 and 28/06/2021 respectively.
122,550	Nil exercise price, options vesting in two equal tranches on 16/07/2020 and 16/07/2021 respectively.
391,566	Nil exercise price rights expiring 30/10/2021, vesting upon achievement of performance hurdles by 30/06/2021.
1,648,971	Nil exercise price, options expiring 30/10/2021, vesting upon achievement of retention and performance hurdles by 30/06/2021.
648,414	Nil exercise price, options expiring 30/10/2020, vesting upon achievement of performance hurdles by 30/06/2019 and retention hurdle on 30/06/2020.
43,268	Nil exercise price, options expiring 13/01/2021, vesting upon achievement of retention hurdles by 13/11/2020.
51,160	Nil exercise price, options expiring 03/10/2021, vesting upon achievement of retention and performance hurdles on 30/06/2021.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Same as applies to the Company's existing Shares

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	N/A
12	Datia in subjab the tagassitica will	NT / A
13	Ratio in which the <sup>+</sup> securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the	NI / A
14	offer relates	N/A
15	<sup>+</sup> Record date to determine	N/A
13	entitlements	N/A
16	Will holdings on different	NI / A
10	registers (or subregisters) be	N/A
	aggregated for calculating	
	entitlements?	
		F
17	Policy for deciding entitlements in relation to fractions	N/A
	relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A

<sup>+</sup> See chapter 19 for defined terms.

25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
	<b>3 - Quotation of securit</b> ed only complete this section if you are app  Type of *securities	
34	(tick one)	
(a)	+Securities described in Part	:1
(b)		end of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Tick to docum	to indicate you are providing the information or ments	
35	1 1	the names of the 20 largest holders of the and percentage of additional *securities
36	If the *securities are *equity securities,	a distribution schedule of the additional ders in the categories
37	A copy of any trust deed for the addition	al <sup>+</sup> securities
Entit	ities that have ticked box 34(b)	
38	Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)	

<sup>+</sup> See chapter 19 for defined terms.

42 Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 20 November 2019

**Company Secretary** 

Print name: Paul Wenk

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues excee	eding 15% of capital
Step 1: Calculate "A", the base figure fr	om which the placement capacity is
<b>Insert</b> number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	250,012,768
Add the following:	Issued under an exception to Listing Rule 7.2:
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	- 190,833 fully paid ordinary securities issued on 11 December 2018
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder</li> </ul>	- 50,000 fully paid ordinary securities issued on 4 March 2019
approval	- 700,002 fully paid ordinary securities issued on 11 June 2019
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	- 186,358 fully paid ordinary securities issued on 18 July 2019
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the	- 3,613,231 fully paid ordinary securities issued on 30 August, 2 September, and 6 September 2019
subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items	- 51,091,614 fully paid ordinary securities to be issued under the Entitlement Offer (included in this calculation pursuant to the waiver granted by ASX to the Company on 8 November 2019)
	- 43,268 fully paid ordinary securities issued on 20 November 2019
	Nil partly paid ordinary securities that became fully paid in the 12 month period
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil

<sup>+</sup> See chapter 19 for defined terms.

"A"

Appendix 3B Page 10 04/03/2013

305,888,074

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	45,883,211
Step 3: Calculate "C", the amount of plants already been used	acement capacity under rule 7.1 tha
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	704,878 fully paid ordinary securities issued on 22 July 2019 on buy-back of contractual obligations.
<ul> <li>Under an exception in rule 7.2</li> </ul>	18,824,660 fully paid ordinary securities issued under the Placement.
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	19,529,538
Step 4: Subtract "C" from ["A" x "B"] to capacity under rule 7.1  "A" x 0.15	o calculate remaining placement 45,883,211
Note: number must be same as shown in Step 2	
Subtract "C"	19,529,538
oubtract c	
Note: number must be same as shown in Step 3  Total ["A" x 0.15] – "C"	26,353,673

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
Step 3: Calculate "E", the amount 7.1A that has already been used  Insert number of *equity securities issued or agreed to be issued in that 12 month	of placement capacity under rule
period under rule 7.1A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.